Kaleen N Hayes Ulrike Baschant Barbara Hauser Andrea M Burden Elizabeth M Winter
10.3389/fendo.2021.782118
Front Endocrinol (Lausanne)
2021 Dec 15;12:782118.
anti-resorptive treatment bisphosphonates bone density bone density conservation agents bone fractures glucocorticoid-induced osteoporosis glucocorticoids teriparatide
CC BY
https://pubmed.ncbi.nlm.nih.gov/34975756/
Bone Density / drug effects Bone Density Conservation Agents / administration & dosage Glucocorticoids / adverse effects Osteoporosis / chemically induced Osteoporosis / drug therapy Withholding Treatment
Bone Density / drug effects Bone Density Conservation Agents / administration & dosage Glucocorticoids / adverse effects Osteoporosis / chemically induced Osteoporosis / drug therapy Withholding Treatment Case Reports Review Bone Density / physiology Female Fractures, Bone / diagnostic imaging Fractures, Bone / prevention & control Glucocorticoids / administration & dosage Humans Lupus Erythematosus, Systemic / diagnostic imaging Lupus Erythematosus, Systemic / drug therapy Middle Aged Osteoporosis / diagnostic imaging Time-to-Treatment Bone Density Conservation Agents Glucocorticoids
PMC8715727
34975756
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis
2021